Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative sintilimab + ipilimumab N01 + SOX in resectable HER2-negative PD-L1-positive MSS/pMMR gastric or gastroesophageal junction adenocarcinoma
ChiCTR2600135518Phase 2Not yet recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, ipilimumab, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Medical Center of Chinese PLA General Hospital. Primary endpoint: Pathological complete response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumabtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600135518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135518.